Using electrical impedance tomography to predict COPD severity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to predict the severity of chronic obstructive pulmonary disease (COPD) by utilizing electrical impedance tomography (EIT) to assess lung structure. It involves collecting pulmonary function data, CT visual scores, and EIT data, and applying deep machine learning algorithms to evaluate the predictive capabilities of EIT compared to traditional pulmonary function tests. The goal is to establish a non-invasive method for monitoring the progression of COPD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical physicians suspect a patient may have COPD based on symptoms and physical examination, but a definitive diagnosis has not been confirmed through PFTs.
* Age \> 20 years, and be able to communicate with doctors.
* Willing to sign informed consent for the course of the study.

Exclusion Criteria:

* Patient refusal of EIT examination.
* The CT scan information is incomplete, and the interval between the pulmonary function test and the CT scan is more than 180 days.

Where it's running

• Pla
  Beijing, Beijing, China Recruiting

Study contacts

• Study coordinator: Zhimei Duan, doctor
• Email: 549117002@qq.com
• Phone: 13716376758

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ensa?fentrine to help prevent COPD flare-ups in adults on standard care

  This study tests whether ensifentrine (MK-5884) can help prevent moderate or severe COPD exacerbations compared with placebo in adults already receiving standard COPD treatment.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Hialeah Gardens, Florida and 6 other locations · NCT07874815

• GSK Investigational Medicine GSK3862995B: two formulations in healthy adults

  This early-phase study tests two formulations of GSK3862995B in healthy adults to see how the body handles the drug and whether it is safe and tolerable.

  Recruiting Phase 1 GlaxoSmithKline · Cambridge · NCT07789899

• GSK5784283 added to standard COPD therapy vs placebo in moderate to very severe COPD

  This study tests whether adding GSK5784283 to current COPD treatment reduces the rate of COPD flare-ups in adults with eosinophilic COPD and a history of exacerbations.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · Doral, Florida and 6 other locations · NCT07780669

• GSK5784283 added to standard COPD care versus placebo in adults with moderate to very severe COPD

  This study tests whether adding GSK5784283 to a patient’s current COPD treatment helps reduce COPD flare-ups compared with a placebo in adults with eosinophilic COPD and a history of frequent exacerbations.

  Recruiting at 8 sites Phase 3 GlaxoSmithKline · Cape Coral, Florida and 7 other locations · NCT07780656

• Brenipatide for adults with moderate-to-severe COPD

  This study tests different doses of Brenipatide to see if it is safe and effective for adults with moderate-to-severe COPD, compared with placebo.

  Recruiting at 69 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 126 other locations · NCT07759245

• Ear (auricular) vagus nerve stimulation to see if a short session changes breathing test results

  This will test whether a brief, non-invasive electrical stimulation of the outer ear changes spirometry (breathing) measurements in healthy adults aged 18–40.

  Recruiting Sinop University · Sinop · NCT07482930

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.